NZ598455A - Compounds as tyrosine kinase modulators - Google Patents
Compounds as tyrosine kinase modulatorsInfo
- Publication number
- NZ598455A NZ598455A NZ598455A NZ59845510A NZ598455A NZ 598455 A NZ598455 A NZ 598455A NZ 598455 A NZ598455 A NZ 598455A NZ 59845510 A NZ59845510 A NZ 59845510A NZ 598455 A NZ598455 A NZ 598455A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- retinal
- neovascularization
- edema
- fluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 208000004644 retinal vein occlusion Diseases 0.000 abstract 2
- SPGOVUHEKLSWMN-UHFFFAOYSA-N 7-[3-fluoro-4-[(2-fluoro-5-methylphenyl)carbamoylamino]phenoxy]thieno[3,2-b]pyridine-2-carboxylic acid Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C(=CC(OC=3C=4SC(=CC=4N=CC=3)C(O)=O)=CC=2)F)=C1 SPGOVUHEKLSWMN-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010058202 Cystoid macular oedema Diseases 0.000 abstract 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000001344 Macular Edema Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010183 Papilledema Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 206010038886 Retinal oedema Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 201000010206 cystoid macular edema Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024519 eye neoplasm Diseases 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 201000008106 ocular cancer Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 201000011195 retinal edema Diseases 0.000 abstract 1
- 208000032253 retinal ischemia Diseases 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23960309P | 2009-09-03 | 2009-09-03 | |
| US30661610P | 2010-02-22 | 2010-02-22 | |
| US35669910P | 2010-06-21 | 2010-06-21 | |
| US36053110P | 2010-07-01 | 2010-07-01 | |
| PCT/US2010/047816 WO2011029001A1 (en) | 2009-09-03 | 2010-09-03 | Compounds as tyrosine kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598455A true NZ598455A (en) | 2014-03-28 |
Family
ID=43086186
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598455A NZ598455A (en) | 2009-09-03 | 2010-09-03 | Compounds as tyrosine kinase modulators |
| NZ598781A NZ598781A (en) | 2009-09-03 | 2010-09-03 | Compounds as tyrosine kinase modulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598781A NZ598781A (en) | 2009-09-03 | 2010-09-03 | Compounds as tyrosine kinase modulators |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8809534B2 (enExample) |
| EP (2) | EP2473513B1 (enExample) |
| JP (3) | JP2013503903A (enExample) |
| KR (2) | KR20120082890A (enExample) |
| CN (2) | CN102686577A (enExample) |
| AU (2) | AU2010289359A1 (enExample) |
| BR (2) | BR112012004843A2 (enExample) |
| CA (2) | CA2772718C (enExample) |
| CL (2) | CL2012000587A1 (enExample) |
| ES (1) | ES2730086T3 (enExample) |
| IL (2) | IL218332A0 (enExample) |
| IN (1) | IN2012DN02493A (enExample) |
| MX (2) | MX2012002591A (enExample) |
| NZ (2) | NZ598455A (enExample) |
| PH (1) | PH12014500281A1 (enExample) |
| RU (2) | RU2012112151A (enExample) |
| SG (2) | SG178963A1 (enExample) |
| WO (2) | WO2011029001A1 (enExample) |
| ZA (2) | ZA201201592B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| JP5658664B2 (ja) | 2008-06-25 | 2015-01-28 | フォルム ファーマシューティカルズ、インコーポレイテッド | １，２−二置換複素環式化合物 |
| EP2532657B9 (en) | 2008-10-14 | 2017-04-19 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| AU2010229147B2 (en) | 2009-03-21 | 2012-07-05 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| CA2761032A1 (en) | 2009-05-07 | 2010-11-11 | Envivo Pharmaceuticals, Inc. | Phenoxymethyl heterocyclic compounds |
| CA2979355C (en) | 2009-05-18 | 2023-02-21 | Dose Medical Corporation | Drug eluting ocular implant |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| CA2772718C (en) * | 2009-09-03 | 2018-02-20 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8906944B2 (en) * | 2009-09-03 | 2014-12-09 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US9045493B2 (en) * | 2012-02-09 | 2015-06-02 | Merck Patent Gmbh | Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives |
| WO2015069287A1 (en) * | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| JP6879740B2 (ja) * | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| CA2932353A1 (en) | 2013-12-13 | 2015-06-18 | Steven P. Treon | Methods to treat lymphoplasmacytic lymphoma |
| CN106866623A (zh) * | 2014-04-08 | 2017-06-20 | 北大方正集团有限公司 | 多取代的吡啶化合物、制备方法、用途及药物组合物 |
| WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| CN104326985A (zh) * | 2014-09-24 | 2015-02-04 | 安润医药科技（苏州）有限公司 | 利你法尼的制备方法 |
| EP3209648B1 (en) | 2014-10-22 | 2020-03-11 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| CN107531679B (zh) * | 2016-03-18 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 芳香酰胺类衍生物、其制备方法及其在医药上的应用 |
| CA3022830A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
| CN107663202B (zh) * | 2016-07-29 | 2020-09-04 | 西华大学 | 3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用 |
| CN110799193B (zh) | 2017-03-21 | 2023-12-12 | 斯克利普斯研究院 | 铜和镍催化的脱羧硼化反应 |
| CA3062602A1 (en) | 2017-05-11 | 2018-11-15 | Bristol-Myers Squibb Company | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
| CN110770210A (zh) * | 2017-05-18 | 2020-02-07 | Pi工业有限公司 | 新颖的脒化合物 |
| SI3860998T1 (sl) | 2018-10-05 | 2024-06-28 | Annapurna Bio Inc. | Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| US5326905A (en) | 1990-04-02 | 1994-07-05 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
| JPH08503450A (ja) | 1992-08-06 | 1996-04-16 | ワーナー−ランバート・コンパニー | 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド） |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| WO1999020617A1 (en) * | 1997-10-21 | 1999-04-29 | Active Biotech Ab | Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors |
| DE60126997T2 (de) * | 2000-10-20 | 2007-10-25 | Eisai R&D Management Co., Ltd. | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
| WO2002090352A2 (de) | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
| US6765012B2 (en) | 2001-09-27 | 2004-07-20 | Allergan, Inc. | 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| US6541504B1 (en) | 2002-04-03 | 2003-04-01 | Allergan Sales, Llc | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| TWI319387B (en) * | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| US20050058689A1 (en) | 2003-07-03 | 2005-03-17 | Reactive Surfaces, Ltd. | Antifungal paints and coatings |
| US6747025B1 (en) | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| MXPA05009102A (es) * | 2003-02-28 | 2006-05-31 | Bayer Pharmaceuticals Corp | Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos. |
| US20070020704A1 (en) * | 2003-05-20 | 2007-01-25 | Scott Wilhelm | Diaryl ureas with kinase inhibiting activity |
| EP1660503A1 (en) * | 2003-08-29 | 2006-05-31 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
| MXPA06002296A (es) * | 2003-08-29 | 2006-05-22 | Pfizer | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. |
| EP1753428A4 (en) * | 2004-05-14 | 2010-09-15 | Abbott Lab | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS |
| MX2007007574A (es) * | 2004-12-22 | 2007-07-24 | Astrazeneca Ab | Derivados de piridina-carboxamida para uso como agentes anticancerosos. |
| NZ590359A (en) | 2005-01-25 | 2012-08-31 | Synta Pharmaceuticals Corp | Pyrazine compounds for inflammation and immune-related uses |
| JP5221147B2 (ja) * | 2005-01-25 | 2013-06-26 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫に関連する用途に用いる化合物 |
| US20060223849A1 (en) | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| ES2473341T3 (es) | 2005-05-20 | 2014-07-04 | Methylgene Inc | Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF |
| WO2006133006A2 (en) * | 2005-06-03 | 2006-12-14 | Bayer Healthcare Ag | 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| WO2007076474A1 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| WO2008063202A2 (en) | 2006-01-30 | 2008-05-29 | Array Biopharma Inc. | Heterobicyclic thiophene compounds for the treatment of cancer |
| ATE453635T1 (de) * | 2006-03-22 | 2010-01-15 | Vertex Pharma | C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen |
| AR060061A1 (es) | 2006-03-22 | 2008-05-21 | Methylgene Inc | Inhibidores de la actividad de la proteina tirosina quinasa |
| US7790756B2 (en) * | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| AU2008242767A1 (en) * | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| EP2452937A1 (en) * | 2007-04-30 | 2012-05-16 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| CA2697795C (en) * | 2007-08-29 | 2016-08-16 | Methylgene Inc. | Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity |
| ES2593279T3 (es) | 2007-08-29 | 2016-12-07 | Methylgene Inc. | Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados |
| US20090118276A1 (en) | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
| WO2009070328A1 (en) | 2007-11-26 | 2009-06-04 | The Regents Of The University Of California | Modulators of the epidermal growth factor receptor (egfr) pathway for use in the treatment or prevention of substance abuse |
| WO2009103778A1 (en) * | 2008-02-19 | 2009-08-27 | Novasaid Ab | Compounds and methods |
| RU2533827C2 (ru) * | 2008-03-05 | 2014-11-20 | Метилджин Инк. | Ингибиторы активности протеинтирозинкиназы |
| WO2010036629A2 (en) * | 2008-09-26 | 2010-04-01 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| CA2772718C (en) | 2009-09-03 | 2018-02-20 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8906944B2 (en) * | 2009-09-03 | 2014-12-09 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
-
2010
- 2010-09-03 CA CA2772718A patent/CA2772718C/en active Active
- 2010-09-03 RU RU2012112151/04A patent/RU2012112151A/ru not_active Application Discontinuation
- 2010-09-03 US US12/875,223 patent/US8809534B2/en active Active
- 2010-09-03 JP JP2012528089A patent/JP2013503903A/ja active Pending
- 2010-09-03 RU RU2012109233/04A patent/RU2012109233A/ru not_active Application Discontinuation
- 2010-09-03 CN CN2010800482682A patent/CN102686577A/zh active Pending
- 2010-09-03 SG SG2012015038A patent/SG178963A1/en unknown
- 2010-09-03 EP EP10752975.2A patent/EP2473513B1/en not_active Not-in-force
- 2010-09-03 US US12/875,218 patent/US8614234B2/en active Active
- 2010-09-03 CA CA2772625A patent/CA2772625A1/en not_active Abandoned
- 2010-09-03 IN IN2493DEN2012 patent/IN2012DN02493A/en unknown
- 2010-09-03 BR BR112012004843A patent/BR112012004843A2/pt not_active IP Right Cessation
- 2010-09-03 MX MX2012002591A patent/MX2012002591A/es not_active Application Discontinuation
- 2010-09-03 NZ NZ598455A patent/NZ598455A/en not_active IP Right Cessation
- 2010-09-03 BR BR112012004718A patent/BR112012004718A2/pt not_active IP Right Cessation
- 2010-09-03 AU AU2010289359A patent/AU2010289359A1/en not_active Abandoned
- 2010-09-03 KR KR1020127008525A patent/KR20120082890A/ko not_active Withdrawn
- 2010-09-03 WO PCT/US2010/047816 patent/WO2011029001A1/en not_active Ceased
- 2010-09-03 JP JP2012528084A patent/JP5868855B2/ja not_active Expired - Fee Related
- 2010-09-03 SG SG2012015053A patent/SG178965A1/en unknown
- 2010-09-03 CN CN2010800389522A patent/CN102498114A/zh active Pending
- 2010-09-03 KR KR1020127008527A patent/KR20120047313A/ko not_active Withdrawn
- 2010-09-03 EP EP10760159.3A patent/EP2473501B1/en not_active Not-in-force
- 2010-09-03 MX MX2012002596A patent/MX2012002596A/es not_active Application Discontinuation
- 2010-09-03 AU AU2010289353A patent/AU2010289353B2/en not_active Ceased
- 2010-09-03 ES ES10760159T patent/ES2730086T3/es active Active
- 2010-09-03 NZ NZ598781A patent/NZ598781A/en not_active IP Right Cessation
- 2010-09-03 WO PCT/US2010/047800 patent/WO2011028995A1/en not_active Ceased
-
2012
- 2012-02-27 IL IL218332A patent/IL218332A0/en unknown
- 2012-02-28 IL IL218374A patent/IL218374A0/en unknown
- 2012-03-02 CL CL2012000587A patent/CL2012000587A1/es unknown
- 2012-03-02 CL CL2012000592A patent/CL2012000592A1/es unknown
- 2012-03-02 ZA ZA2012/01592A patent/ZA201201592B/en unknown
- 2012-03-05 ZA ZA2012/01627A patent/ZA201201627B/en unknown
-
2013
- 2013-10-15 US US14/054,444 patent/US9328103B2/en active Active
-
2014
- 2014-02-03 PH PH12014500281A patent/PH12014500281A1/en unknown
-
2015
- 2015-07-08 US US14/793,913 patent/US9475801B2/en active Active
-
2016
- 2016-01-06 JP JP2016001387A patent/JP6109974B2/ja not_active Expired - Fee Related
- 2016-09-19 US US15/269,612 patent/US9725433B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598455A (en) | Compounds as tyrosine kinase modulators | |
| ZA202109122B (en) | A process for the manufacturing of (6ar,10ar)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinoline and (4ar,10ar)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol | |
| HK1203375A1 (en) | Method for treating a gd2 positive cancer | |
| PH12017501661A1 (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
| NZ708183A (en) | Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| WO2010141796A3 (en) | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| HK1211599A1 (en) | Il-6 antagonists and uses thereof | |
| WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| MY147890A (en) | 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer | |
| WO2014110086A3 (en) | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof | |
| NZ605022A (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| MY176514A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| IN2012DN02826A (enExample) | ||
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| WO2012141796A3 (en) | Prostate cancer therapy with hsp90 inhibitory compounds | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| TN2019000117A1 (en) | Liposomal formulation for use in the treatment of cancer | |
| NZ597916A (en) | Benzoquinolizinium salt derivatives as anticancer agents | |
| CN103172641B (zh) | 杂环胺基烷氧基取代的喹唑啉衍生物及其用途 | |
| WO2007089673A3 (en) | Compositions and methods for treatment of ophthalmic diseases and disorders | |
| MX2009006077A (es) | Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6. | |
| WO2011009826A3 (en) | Novel chalcone derivatives with cytotoxic activity | |
| IL201491A0 (en) | Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |